Anterior ocular infections: an overview of pathophysiology and treatment.
OBJECTIVE
To provide a review of the pathophysiology and treatment of anterior ocular infections.


METHODS
A MEDLINE search (from 1970 to October 1998) as well as a review of the tertiary literature was performed to identify pertinent literature on pathophysiology and treatment of ocular infections.


METHODS
All articles were considered for possible inclusion in the review. Relevant studies were selected for discussion in the article.


RESULTS
Ocular infections are common and vary from self-limiting to sight-threatening. Infections occur in different eye structures; presentation and treatment vary accordingly. Infections can occur when tissues of the eye are exposed to pathogens not normally present, when the eye is damaged, allowing pathogens to overcome the natural defenses of the eye, or in immunosuppressed patients where normal flora may become opportunistic. In deciding on appropriate treatment, both the causative pathogen and the structure(s) affected must be considered. The most likely pathogen can often be determined based on clinical signs and symptoms, patient history, or, in some cases, may need to be determined microbiologically. Differences in drug absorption, penetration, and availability to the various structures of the eye affect treatment decisions. Severity of infection, efficacy and safety of medication, and cost/benefit ratios must be taken into consideration in choosing the proper pharmacologic management of various ocular infections.


CONCLUSIONS
Treatment of ocular infections depends on knowledge of the pathophysiology and drug disposition at the site of infection. An understanding of the current concepts surrounding the management of the anterior ocular infections presented will aid in the provision of optimal patient care.
Thielen
T L
TL
WJB Dorn Veterans Affairs Medical Center, Columbia, SC, USA.
Castle
S S
SS
Terry
J E
JE
D000867:Anterior Chamber; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003234:Conjunctivitis, Bacterial / Q000188:drug therapy; D015817:Eye Infections / Q000188:drug therapy* / Q000503:physiopathology*; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000503:physiopathology; D015821:Eye Infections, Fungal / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans
D000890:Anti-Infective Agents